BACKGROUND AND PURPOSE: Natalizumab treatment strongly affects relapsing-remitting
multiple sclerosis, possibly by restraining white matter damage. This study investigated …

Background: Since cortical pathology has been indicated to play a relevant role in the
physical and cognitive disability of multiple sclerosis (MS) patients, this study aims to …

Background: In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in
Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients with …

In this prospective post-marketing study, 21 patients with multiple sclerosis treated with
natalizumab for 24 consecutive months elected a trial of treatment interruption (90–180 …

Background and purpose The long‐term benefit of natalizumab on brain atrophy
progression in multiple sclerosis (MS) patients is unknown. Our aim was to investigate its …

The SENTINEL study showed that the addition of natalizumab improved outcomes for
patients with relapsing multiple sclerosis (MS) who had experienced disease activity while …

Natalizumab discontinuation is associated with a disease reactivation in multiple sclerosis
(MS) patients. Whether this reactivation involves also cognitive functions is not known to …

Background Relapsing-remitting multiple sclerosis (RRMS) is the most common phenotype
of multiple sclerosis (MS), and its active stage is characterized by active T2 lesions with or …

In clinical practice natalizumab is typically used in patients who have experienced
breakthrough disease during treatment with interferon beta (IFNβ) or glatiramer acetate. In …

Background The efficacy of natalizumab on clinical and radiological measures in the phase
III Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) …